{"success":true,"data":{"pressRelease":{"id":"66530","rtpr_id":"nPn7P3B74a","ticker":"LNAI","exchange":"NASDAQ","all_tickers":["LNAI"],"title":"LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS","author":"PR Newswire","published_at":"2026-06-17T13:15:00.043Z","article_body":"LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS\n\nPR Newswire\n\nSACRAMENTO, Calif., June 17, 2026\n\nSACRAMENTO, Calif., June 17, 2026 /PRNewswire/ --\n\nFellow Shareholders,\n\nOver the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to\nexecute its strategy of building a next-generation biotechnology company at\nthe intersection of artificial intelligence, and national security and\nbiology. I would like to update you on developments that have substantially\nstrengthened our position and created multiple pathways for shareholder value\ncreation.\n\nA RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORM\n\nIn April 2026, we secured our first revenue-generating, multi-year defense\ncollaboration through BioSymetrics to deploy our AI-enabled platform for\nchemical threat assessment. This contract represents not a research\nrelationship but an active commercial engagement with the U.S. government.\n\nBeyond that initial contract, we have established the Pathfinder\nConsortium—a national alliance of leading institutions including Harvard\nUniversity, Brigham and Women's Hospital (led by Dr. Calum MacRae), the\nUniversity of Utah, Purdue University, and the University of Colorado. These\npartnerships reflect the scientific rigor and national security relevance of\nour approach.\n\nLooking forward to the second half of 2026 we believe our Augusta platform\nwhich combines Contingent AI, large toxicity databases, and in vivo testing\naligns with the priorities outlined in the 2027 Defense Authorization Bill\npublished this month. It specifically calls for the nation \"to develop a\nstrategy to leverage artificial intelligence-enabled and high-throughput\nbiological screening approaches in support of identifying and characterizing\npotential chemical neurotoxic threat agents\". This is precisely what we are\ndoing under our current contract and further involves the capabilities we now\nhave with the Pathfinder Consortium.\n\nPRECISION NEUROLOGY: A COMPLEMENTARY GROWTH ENGINE\n\nIn parallel, Lunai continues to advance its precision neurology pipeline\nthrough our Augusta™ AI platform in Epilepsy, Parkinsons, and Alzheimer's.\nWe recently announced and are advancing collaborations including a partnership\nwith BrainStorm Therapeutics supported by foundation funding, and we continue\nto benefit from NIH-supported research initiatives, including a Phase I/II\nSTTR grant ($1.85 million awarded to BioSymetrics) for alcohol use disorder\nresearch. These partnerships represent external validation of our\nbiology-first discovery approach.\n\nNeurological diseases remain among the most challenging and costly medical\nconditions, affecting millions of patients worldwide. By combining large-scale\npatient datasets with advanced AI analytics and validated with in vivo\ntesting, we are identifying therapeutic opportunities that conventional\nmethods miss. This work represents a significant long-term value driver for\nLunai, and one that is independent of our biodefense activities.\n\nTHE CONVERGENCE: AI, BIOTECHNOLOGY, AND THE FULL SPECTRUM OF BIOLOGICAL\nTHREATS\n\nThe strategic importance of biodefense is increasingly recognized by\ngovernments, scientists, and technology leaders worldwide.\n\nRecently, the chief executives of Anthropic, OpenAI, Google DeepMind, and\nMicrosoft AI, alongside numerous leaders from biotechnology and national\nsecurity organizations, signed a public letter supporting enhanced safeguards\naround synthetic DNA and nucleic acid synthesis technologies. The letter\nhighlights a fundamental concern: advances in artificial intelligence are\nrapidly reducing barriers to the design and engineering of biological agents.\n\nThis is not theoretical. The risks are dual: engineered biological threats\nfrom state and non-state actors, and the accelerating risk of novel\npandemics—whether natural or human-engineered. The line between public\nhealth preparedness and national security has blurred entirely. COVID\ndemonstrated the global health and economic cost of a biological event. The\nprospect of deliberate bioweapon creation through synthetic biology represents\nan equally grave but far less recognized threat.\n\nGovernments are responding. The recognition that the next biological\ncrisis—pandemic or weaponized—could originate from either natural\nevolution or deliberate engineering is driving substantial investment in\ndetection, identification, and countermeasure development at speeds and scales\npreviously reserved for kinetic warfare.\n\nLunai's current biodefense activities focus on chemical threat assessment\nthrough our first revenue-generating defense contract and the Pathfinder\nConsortium. However, our AI-driven platform for threat identification,\nphenotypic screening, and countermeasure discovery is directly applicable\nacross the full spectrum of biological threats—both pandemic and weaponized.\nWe are actively exploring partnerships and opportunities to expand our\nbiodefense capabilities into biological threat detection and countermeasure\ndevelopment. Given the government's growing recognition of both pandemic and\nbioweapon risks, and our existing partnerships with leading scientific\ninstitutions and federal agencies, we believe we are well-positioned to\nparticipate in what will become a major national security and public health\npriority.\n\nPROTECTING SHAREHOLDER VALUE: LITIGATION AS VALUE UNLOCK\n\nAs we continue to execute and announce meaningful milestones, we have observed\ntrading activity that does not reflect the progress being achieved by Lunai.\n\nIn May 2026, we initiated legal action in the U.S. District Court for the\nDistrict of Delaware against unidentified parties alleged to have engaged in\nnaked short selling and related manipulative trading. The evidence was\nsubstantial: anomalous failing-to-deliver of 29.6 million shares (81.6% of all\noutstanding shares), with peak trading volumes on March 17, 2026, reaching 554\nmillion shares—15.3 times all outstanding shares in a single day.\n\nCritically, the Court found good cause for expedited discovery and established\na prima facie basis for our claims. This rule permits us to obtain trading\nrecords from broker-dealers, custodians, and market participants to identify\nthose responsible. We are now in the discovery process.\n\nThe purpose of this litigation is straightforward: identify the parties\nengaged in improper market activity, hold them accountable, and restore\nshareholder value that has been artificially suppressed. Litigation discovery\nwill force disclosure of positions, trading records, and brokerage\nrelationships that shorts depend on keeping hidden. As those identities\nemerge, regulatory scrutiny of the short positions themselves becomes\ninevitable—and expensive to maintain.\n\nWe intend to pursue this matter vigorously. In our view, protecting\nshareholder interests and pursuing accountability for market manipulation is\nnot a distraction, it is a core responsibility of management.\n\nLOOKING FORWARD\n\nLunai today is substantially different from the company it was a year ago. We\nhave established the first revenue-generating defense contract, assembled a\nnational network of world-class scientific and military partners, continued to\nvalidate our AI-driven approach in both biodefense and precision neurology,\nand initiated legal action to address market manipulation artificially\nsuppressing our stock price.\n\nThe convergence of AI, biotechnology, and national security is creating a rare\nstrategic opportunity. Through our biodefense platform and precision neurology\npipeline, we are building a company positioned to address some of the largest\nand most important markets, backed by government partners and validated by\nleading scientific institutions.\n\nAs we move through the second half of 2026, our focus remains clear: advancing\nand expanding our biodefense platform, neurology programs, executing our\nlitigation strategy, and continuing to validate our platform across both\nhealthcare and national security applications. Now that the company has\nachieved compliance with the NASDAQ listing requirements we are positioned to\nbuild long term value for our shareholders.\n\nI would like to thank you for your continued support.\n\nSincerely,\n\nDavid Weinstein\nChief Executive Officer\nLunai Bioworks, Inc.\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/lunai-bioworks-ceo-letter-to-shareholders-302803131.html\n(https://www.prnewswire.com/news-releases/lunai-bioworks-ceo-letter-to-shareholders-302803131.html)\n\nSOURCE Lunai Bioworks Inc.\n\n\n\nir@lunaibioworks.com, http://www.lunaibioworks.com/\n\nPhoto: \nhttps://mma.prnewswire.com/media/2814530/Lunai_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn7P3B74a","title":"LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS","author":"PR Newswire","ticker":"LNAI","created":"2026-06-17T13:15:00.043Z","tickers":["LNAI"],"exchange":"NASDAQ","article_body":"LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS\n\nPR Newswire\n\nSACRAMENTO, Calif., June 17, 2026\n\nSACRAMENTO, Calif., June 17, 2026 /PRNewswire/ --\n\nFellow Shareholders,\n\nOver the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to\nexecute its strategy of building a next-generation biotechnology company at\nthe intersection of artificial intelligence, and national security and\nbiology. I would like to update you on developments that have substantially\nstrengthened our position and created multiple pathways for shareholder value\ncreation.\n\nA RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORM\n\nIn April 2026, we secured our first revenue-generating, multi-year defense\ncollaboration through BioSymetrics to deploy our AI-enabled platform for\nchemical threat assessment. This contract represents not a research\nrelationship but an active commercial engagement with the U.S. government.\n\nBeyond that initial contract, we have established the Pathfinder\nConsortium—a national alliance of leading institutions including Harvard\nUniversity, Brigham and Women's Hospital (led by Dr. Calum MacRae), the\nUniversity of Utah, Purdue University, and the University of Colorado. These\npartnerships reflect the scientific rigor and national security relevance of\nour approach.\n\nLooking forward to the second half of 2026 we believe our Augusta platform\nwhich combines Contingent AI, large toxicity databases, and in vivo testing\naligns with the priorities outlined in the 2027 Defense Authorization Bill\npublished this month. It specifically calls for the nation \"to develop a\nstrategy to leverage artificial intelligence-enabled and high-throughput\nbiological screening approaches in support of identifying and characterizing\npotential chemical neurotoxic threat agents\". This is precisely what we are\ndoing under our current contract and further involves the capabilities we now\nhave with the Pathfinder Consortium.\n\nPRECISION NEUROLOGY: A COMPLEMENTARY GROWTH ENGINE\n\nIn parallel, Lunai continues to advance its precision neurology pipeline\nthrough our Augusta™ AI platform in Epilepsy, Parkinsons, and Alzheimer's.\nWe recently announced and are advancing collaborations including a partnership\nwith BrainStorm Therapeutics supported by foundation funding, and we continue\nto benefit from NIH-supported research initiatives, including a Phase I/II\nSTTR grant ($1.85 million awarded to BioSymetrics) for alcohol use disorder\nresearch. These partnerships represent external validation of our\nbiology-first discovery approach.\n\nNeurological diseases remain among the most challenging and costly medical\nconditions, affecting millions of patients worldwide. By combining large-scale\npatient datasets with advanced AI analytics and validated with in vivo\ntesting, we are identifying therapeutic opportunities that conventional\nmethods miss. This work represents a significant long-term value driver for\nLunai, and one that is independent of our biodefense activities.\n\nTHE CONVERGENCE: AI, BIOTECHNOLOGY, AND THE FULL SPECTRUM OF BIOLOGICAL\nTHREATS\n\nThe strategic importance of biodefense is increasingly recognized by\ngovernments, scientists, and technology leaders worldwide.\n\nRecently, the chief executives of Anthropic, OpenAI, Google DeepMind, and\nMicrosoft AI, alongside numerous leaders from biotechnology and national\nsecurity organizations, signed a public letter supporting enhanced safeguards\naround synthetic DNA and nucleic acid synthesis technologies. The letter\nhighlights a fundamental concern: advances in artificial intelligence are\nrapidly reducing barriers to the design and engineering of biological agents.\n\nThis is not theoretical. The risks are dual: engineered biological threats\nfrom state and non-state actors, and the accelerating risk of novel\npandemics—whether natural or human-engineered. The line between public\nhealth preparedness and national security has blurred entirely. COVID\ndemonstrated the global health and economic cost of a biological event. The\nprospect of deliberate bioweapon creation through synthetic biology represents\nan equally grave but far less recognized threat.\n\nGovernments are responding. The recognition that the next biological\ncrisis—pandemic or weaponized—could originate from either natural\nevolution or deliberate engineering is driving substantial investment in\ndetection, identification, and countermeasure development at speeds and scales\npreviously reserved for kinetic warfare.\n\nLunai's current biodefense activities focus on chemical threat assessment\nthrough our first revenue-generating defense contract and the Pathfinder\nConsortium. However, our AI-driven platform for threat identification,\nphenotypic screening, and countermeasure discovery is directly applicable\nacross the full spectrum of biological threats—both pandemic and weaponized.\nWe are actively exploring partnerships and opportunities to expand our\nbiodefense capabilities into biological threat detection and countermeasure\ndevelopment. Given the government's growing recognition of both pandemic and\nbioweapon risks, and our existing partnerships with leading scientific\ninstitutions and federal agencies, we believe we are well-positioned to\nparticipate in what will become a major national security and public health\npriority.\n\nPROTECTING SHAREHOLDER VALUE: LITIGATION AS VALUE UNLOCK\n\nAs we continue to execute and announce meaningful milestones, we have observed\ntrading activity that does not reflect the progress being achieved by Lunai.\n\nIn May 2026, we initiated legal action in the U.S. District Court for the\nDistrict of Delaware against unidentified parties alleged to have engaged in\nnaked short selling and related manipulative trading. The evidence was\nsubstantial: anomalous failing-to-deliver of 29.6 million shares (81.6% of all\noutstanding shares), with peak trading volumes on March 17, 2026, reaching 554\nmillion shares—15.3 times all outstanding shares in a single day.\n\nCritically, the Court found good cause for expedited discovery and established\na prima facie basis for our claims. This rule permits us to obtain trading\nrecords from broker-dealers, custodians, and market participants to identify\nthose responsible. We are now in the discovery process.\n\nThe purpose of this litigation is straightforward: identify the parties\nengaged in improper market activity, hold them accountable, and restore\nshareholder value that has been artificially suppressed. Litigation discovery\nwill force disclosure of positions, trading records, and brokerage\nrelationships that shorts depend on keeping hidden. As those identities\nemerge, regulatory scrutiny of the short positions themselves becomes\ninevitable—and expensive to maintain.\n\nWe intend to pursue this matter vigorously. In our view, protecting\nshareholder interests and pursuing accountability for market manipulation is\nnot a distraction, it is a core responsibility of management.\n\nLOOKING FORWARD\n\nLunai today is substantially different from the company it was a year ago. We\nhave established the first revenue-generating defense contract, assembled a\nnational network of world-class scientific and military partners, continued to\nvalidate our AI-driven approach in both biodefense and precision neurology,\nand initiated legal action to address market manipulation artificially\nsuppressing our stock price.\n\nThe convergence of AI, biotechnology, and national security is creating a rare\nstrategic opportunity. Through our biodefense platform and precision neurology\npipeline, we are building a company positioned to address some of the largest\nand most important markets, backed by government partners and validated by\nleading scientific institutions.\n\nAs we move through the second half of 2026, our focus remains clear: advancing\nand expanding our biodefense platform, neurology programs, executing our\nlitigation strategy, and continuing to validate our platform across both\nhealthcare and national security applications. Now that the company has\nachieved compliance with the NASDAQ listing requirements we are positioned to\nbuild long term value for our shareholders.\n\nI would like to thank you for your continued support.\n\nSincerely,\n\nDavid Weinstein\nChief Executive Officer\nLunai Bioworks, Inc.\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/lunai-bioworks-ceo-letter-to-shareholders-302803131.html\n(https://www.prnewswire.com/news-releases/lunai-bioworks-ceo-letter-to-shareholders-302803131.html)\n\nSOURCE Lunai Bioworks Inc.\n\n\n\nir@lunaibioworks.com, http://www.lunaibioworks.com/\n\nPhoto: \nhttps://mma.prnewswire.com/media/2814530/Lunai_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-17T13:15:00.089729908Z","server_sent_at_ms":1781702100089},"received_at":"2026-06-17T13:15:00.161Z","source_url":"https://www.prnewswire.com/news-releases/lunai-bioworks-ceo-letter-to-shareholders-302803131.html"},"analysis":{"id":"55947","press_release_id":"66530","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Litigation alleges naked short selling of 29.6 million shares (81.6% of float)","Peak trading volume of 554 million shares (15.3x outstanding) cited in lawsuit"],"eventType":"operations_update","narrative":"Lunai Bioworks announced its first revenue-generating defense contract for chemical threat assessment and formed the Pathfinder Consortium with major universities including Harvard and Purdue.\n\nThe company confirmed that the U.S. District Court for the District of Delaware granted expedited discovery in a lawsuit alleging naked short selling, citing anomalous failing-to-deliver of 29.6 million shares representing 81.6% of outstanding shares.\n\nManagement noted the company has achieved compliance with NASDAQ listing requirements and continues to advance its precision neurology pipeline through partnerships and NIH-supported grants.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"First revenue secured plus court approval to pursue claims over 81.6% FTD rate."},"keyFigures":{"customDimensions":{"ftd_shares":"29.6 million","ftd_percentage":"81.6%","sttr_grant_usd":"$1.85 million","peak_volume_shares":"554 million","peak_volume_multiple":"15.3x"}},"quotedText":"In our view, protecting shareholder interests and pursuing accountability for market manipulation is not a distraction, it is a core responsibility of management.","namedEntities":{"people":[{"name":"David Weinstein","role":"CEO"},{"name":"Dr. Calum MacRae","role":"Partner (Brigham and Women's Hospital)"}],"products":["Augusta platform"],"companies":[{"name":"Lunai Bioworks","ticker":"LNAI"},{"name":"BioSymetrics","relationship":"partner"},{"name":"BrainStorm Therapeutics","relationship":"partner"},{"name":"Harvard University","relationship":"partner"},{"name":"Brigham and Women's Hospital","relationship":"partner"},{"name":"University of Utah","relationship":"partner"},{"name":"Purdue University","relationship":"partner"},{"name":"University of Colorado","relationship":"partner"},{"name":"Anthropic","relationship":"mentioned"},{"name":"OpenAI","relationship":"mentioned"},{"name":"Google DeepMind","relationship":"mentioned"},{"name":"Microsoft AI","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$1.85 million","context":"Phase I/II STTR grant awarded to BioSymetrics"}]},"materialImpact":{"score":4,"reasoning":"Company achieved its first revenue-generating defense contract and confirmed NASDAQ compliance. Additionally, the U.S. District Court granted expedited discovery in a lawsuit alleging massive naked short selling, finding a prima facie basis for claims of 29.6 million failing-to-deliver shares."},"tickerRelevance":{"others":[],"primary":"LNAI"},"globalImportance":25,"audienceRelevance":35,"eventTypeSecondary":["legal_litigation"],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"first-revenue-and-major-litigation","retailInterest":"high-due-to-short-interest-claims"}},"event_type":"operations_update","event_type_secondary":["legal_litigation"],"sentiment":"bullish","material_impact_score":4,"narrative":"Lunai Bioworks announced its first revenue-generating defense contract for chemical threat assessment and formed the Pathfinder Consortium with major universities including Harvard and Purdue.\n\nThe company confirmed that the U.S. District Court for the District of Delaware granted expedited discovery in a lawsuit alleging naked short selling, citing anomalous failing-to-deliver of 29.6 million shares representing 81.6% of outstanding shares.\n\nManagement noted the company has achieved compliance with NASDAQ listing requirements and continues to advance its precision neurology pipeline through partnerships and NIH-supported grants.","key_figures":{"customDimensions":{"ftd_shares":"29.6 million","ftd_percentage":"81.6%","sttr_grant_usd":"$1.85 million","peak_volume_shares":"554 million","peak_volume_multiple":"15.3x"}},"named_entities":{"people":[{"name":"David Weinstein","role":"CEO"},{"name":"Dr. Calum MacRae","role":"Partner (Brigham and Women's Hospital)"}],"products":["Augusta platform"],"companies":[{"name":"Lunai Bioworks","ticker":"LNAI"},{"name":"BioSymetrics","relationship":"partner"},{"name":"BrainStorm Therapeutics","relationship":"partner"},{"name":"Harvard University","relationship":"partner"},{"name":"Brigham and Women's Hospital","relationship":"partner"},{"name":"University of Utah","relationship":"partner"},{"name":"Purdue University","relationship":"partner"},{"name":"University of Colorado","relationship":"partner"},{"name":"Anthropic","relationship":"mentioned"},{"name":"OpenAI","relationship":"mentioned"},{"name":"Google DeepMind","relationship":"mentioned"},{"name":"Microsoft AI","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$1.85 million","context":"Phase I/II STTR grant awarded to BioSymetrics"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-17T13:52:59.122Z","global_importance":25,"audience_relevance":35,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"first-revenue-and-major-litigation","retailInterest":"high-due-to-short-interest-claims"}},"durationMs":134283,"modelName":"george-droid-qwen-72b"}}